Literature DB >> 22922634

Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia.

Cheol-In Kang1, Jae-Hoon Song, So Hyun Kim, Doo Ryeon Chung, Kyong Ran Peck, Visanu Thamlikitkul, Hui Wang, Thomas Man-kit So, Po-Ren Hsueh, Rohani Md Yasin, Celia C Carlos, Pham Hung Van, Jennifer Perera.   

Abstract

OBJECTIVE: This study was performed to identify risk factors for the development of bacteremic pneumonia and to evaluate the impact of bacteremia on the outcome of pneumococcal pneumonia.
METHODS: Using a database from a surveillance study of community-acquired pneumococcal pneumonia, we compared data of the bacteremic group with that of the non-bacteremic group.
RESULTS: Among 981 adult patients with pneumococcal pneumonia, 114 (11.6%) patients who had documented pneumococcal bacteremia were classified into the bacteremic group. In a multivariable analysis, use of immunosuppressant drugs, younger age (<65 years), and DM were independent risk factors associated with the development of bacteremic pneumonia among patients with pneumococcal pneumonia (all P < 0.05). The mortality rate was significantly higher in the bacteremic group than in the non-bacteremic group (28.6% vs. 8.5%; P < 0.001). The multivariable analysis revealed that concomitant bacteremia was one of the significant risk factors associated with mortality (OR, 2.57; 95% CI, 1.24-5.29), along with cerebrovascular disease and presentation with septic shock (all P < 0.05).
CONCLUSIONS: Bacteremia was a common finding in pneumococcal pneumonia and was associated with a higher mortality rate. Several clinical variables may be useful for predicting bacteremic pneumonia among patients with pneumococcal pneumonia.
Copyright © 2012. Published by Elsevier Ltd.

Entities:  

Mesh:

Year:  2012        PMID: 22922634     DOI: 10.1016/j.jinf.2012.08.011

Source DB:  PubMed          Journal:  J Infect        ISSN: 0163-4453            Impact factor:   6.072


  16 in total

1.  Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South Korea.

Authors:  Min-Joo Choi; Shin-On Kang; Jin-Jeong Oh; Seong-Beom Park; Min-Ja Kim; Hee-Jin Cheong
Journal:  Hum Vaccin Immunother       Date:  2018-07-11       Impact factor: 3.452

2.  Influence of chronic illnesses and underlying risk conditions on the incidence of pneumococcal pneumonia in older adults.

Authors:  Angel Vila-Corcoles; Carlos Aguirre-Chavarria; Olga Ochoa-Gondar; Cinta de Diego; Teresa Rodriguez-Blanco; Frederic Gomez; Xavier Raga; Luis Barnes; Ramon Magarolas; Leonardo Esteban
Journal:  Infection       Date:  2015-06-03       Impact factor: 3.553

Review 3.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

4.  Bacteremic pneumococcal pneumonia: clinical outcomes and preliminary results of inflammatory response.

Authors:  J M Bordon; R Fernandez-Botran; T L Wiemken; P Peyrani; S M Uriarte; F W Arnold; L Rodriquez-Hernandez; M J Rane; R R Kelley; L E Binford; S Uppatla; R Cavallazzi; F Blasi; S Aliberti; M I Restrepo; S Fazeli; A Mathur; M Rahmani; K Ayesu; J Ramirez
Journal:  Infection       Date:  2015-09-30       Impact factor: 3.553

5.  30-day mortality in UK patients with bacteraemic community-acquired pneumonia.

Authors:  M Melzer; C Welch
Journal:  Infection       Date:  2013-05-24       Impact factor: 3.553

6.  Risk factors for levofloxacin-nonsusceptible Streptococcus pneumoniae in community-acquired pneumococcal pneumonia: a nested case-control study.

Authors:  C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; T M So; P-R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-06       Impact factor: 3.267

7.  Bacteraemic and non-bacteraemic/urinary antigen-positive pneumococcal community-acquired pneumonia compared.

Authors:  S P van Mens; A M M van Deursen; S C de Greeff; H E de Melker; L M Schouls; A van der Ende; M J M Bonten; E A M Sanders; B J M Vlaminckx
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-08-01       Impact factor: 3.267

8.  Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis.

Authors:  Adoración Navarro-Torné; Eva Agostina Montuori; Vasiliki Kossyvaki; Cristina Méndez
Journal:  Hum Vaccin Immunother       Date:  2021-06-09       Impact factor: 4.526

9.  Results of high-risk neutropenia therapy of hematology-oncology patients in a university hospital in Uruguay.

Authors:  Matilde Boada Burutaran; Regina Guadagna; Sofia Grille; Mariana Stevenazzi; Cecilia Guillermo; Lilian Diaz
Journal:  Rev Bras Hematol Hemoter       Date:  2014-11-21

10.  Clinical and economic burden of invasive pneumococcal disease in adults: a multicenter hospital-based study.

Authors:  Joon Young Song; Jun Yong Choi; Jin Soo Lee; In-Gyu Bae; Young Keun Kim; Jang Wook Sohn; Yu Mi Jo; Won Suk Choi; Jacob Lee; Kyung Hwa Park; Woo Joo Kim; Hee Jin Cheong
Journal:  BMC Infect Dis       Date:  2013-05-04       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.